Anavex Life Sciences Corp. reported preliminary second quarter fiscal 2026 financial results ending March 31, 2026. The company recorded a net loss of $5.3 million, or $0.06 per share, compared to a net loss of $11.2 million in the prior year period. Preliminary cash and cash equivalents stood at $127.4 million as of March 31, 2026, up from $102.6 million at September 30, 2025. The company anticipates its current cash balance will fund operations into mid-to-late fiscal 2028. On a business update, Anavex submitted a plan to regain Nasdaq listing compliance on July 20, 2026, and opened an Investigational New Drug application for early Alzheimer’s disease with the FDA at the end of March 2026. Interim CEO Terrie Kellmeyer emphasized a disciplined strategy focusing on blarcamesine for early Alzheimer's, Rett syndrome, and Fragile X syndrome. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases.

On July 20, 2026, Anavex Life Sciences Corp. submitted a Compliance Plan to Nasdaq to regain compliance with Listing Rule 5250(c)(1) following a deficiency notice received on May 20, 2026. The deficiency resulted from the company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. While the common stock continues to trade under the symbol "AVXL", the company's listing status depends on the Nasdaq Staff's review of the plan. Anavex Life Sciences Corp. is a biotechnology company that develops therapeutic candidates for neurological disorders.